drugset
drugset / Trial / NCT03970122

FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects

NCT03970122 ↗

Phase 1 Completed 70 enrolled Goldfinch Bio, Inc.
RandomizedParallel-groupDouble-blindOther

Summary

The study will comprise primarily a single-ascending dose (SAD) escalation component.

Timeline

Start
2019-05-29
Primary completion
2020-03-04
Completion
2020-04-04

Drugs

EvaluationDrugModalityDoseRoute
Subject GFB-887 Small molecule — —

Indications

No indication recorded.